

Iluvien® (fluocinolone acetonide intravitreal implant)



When requesting Iluvien® (fluocinolone acetonide intravitreal implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

- Iluvien® (fluocinolone acetonide intravitreal implant) is indicated for the treatment of diabetic macular edema in individuals who have been previously treated with a course of corticosteroids and who did not have a clinically significant rise in intraocular pressure.

Coverage Guidelines

The individual must meet all of the following criteria for approval:

- Diagnosis of diabetic macular edema
- Previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure
- Does not have an ocular or periocular infection
- Does not have glaucoma with cup to disc ratios > 0.8

Approval duration: 36 months

Dosing Recommendations

- 0.19 mg intravitreal implant

References

1. Iluvien® prescribing information. Alpharetta, GA: Alimera Sciences, Inc.: November 2017.
2. Fluocinolone acetonide, DRUGDEX® system. Thomson Micromedex, Greenwood Village, CO. [Accessed April 17, 2018].
3. Schmidt-Erfurth U et al. Guideline for the Management of Diabetic Macular by the European Society of Retina Specialists (EURETINA). *Ophthalmologica* 2017; 237:185-222.
4. American Academy of Ophthalmology (2012). Preferred Practice Patterns. Noninfectious Uveitis: Optimizing Drug Therapy.